Olmesartan Medoxomil

Olmesartan Medoxomil

CAT N°: 11614
Price:

From 48.00 40.80

Olmesartan medoxomil is an orally bioavailable prodrug form of olmesartan (Item No. 23412), a nonpeptide angiotensin II antagonist that is selective for the angiotensin 1 (AT1) receptor over the AT2 receptor.{20965} Olmesartan medoxomil (0.1 mg/kg) inhibits the angiotensin II pressor response in normotensive rats. It reduces both systolic and diastolic blood pressure in fructose-fed rats, a model of insulin resistance, when administered at a dose of 10 mg/kg per day, as well as in chow-fed control animals when administered at a dose of 11.4 mg/kg per day.{42446} Olmesartan medoxomil also inhibits increases in plasma levels of triglycerides and non-esterified fatty acids in fructose-fed rats. Formulations containing olmesartan medoxomil have been used in the treatment of hypertension.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2’-(2H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
  • Correlated keywords
    • prodrugs angiotensin II receptors antagonists blood pressure hypertension cardiovascular disease atherosclerosis CS866 CS 866 in vivo RNH-6270 RNH 6270 RNH6270 AT1 AT2 blood pressure cardiovascular parameters CS-866 Benicar Olmetec
  • Product Overview:
    Olmesartan medoxomil is an orally bioavailable prodrug form of olmesartan (Item No. 23412), a nonpeptide angiotensin II antagonist that is selective for the angiotensin 1 (AT1) receptor over the AT2 receptor.{20965} Olmesartan medoxomil (0.1 mg/kg) inhibits the angiotensin II pressor response in normotensive rats. It reduces both systolic and diastolic blood pressure in fructose-fed rats, a model of insulin resistance, when administered at a dose of 10 mg/kg per day, as well as in chow-fed control animals when administered at a dose of 11.4 mg/kg per day.{42446} Olmesartan medoxomil also inhibits increases in plasma levels of triglycerides and non-esterified fatty acids in fructose-fed rats. Formulations containing olmesartan medoxomil have been used in the treatment of hypertension.

We also advise you